冠科生物

Crown Bioscience has appointed John Gu as our new Chief Executive Officer (CEO). Following his tenure as interim CEO and his role as Chief Operating Officer (COO), John Gu is recognized as an esteemed leader with broad business acumen and extensive experience in digital strategy, business transformation, and genomic data analysis. His unparalleled experience is particularly relevant in streamlining AI-driven approaches to advance drug discovery and development processes, marking him as a remarkable asset in steering Crown Bioscience to the forefront of biotechnological innovation. Learn more https://hubs.ly/Q03bxGpb0

Do you use cell line-derived xenograft (CDX) models in your oncology drug discovery process? ?? CDX models can provide key decision-making information to allow an agent to move forward, and to advance preclinical drug development in a timely and cost-effective manner. Discover more ?? https://hubs.la/Q03c8xJH0

Crown Bioscience holds an exclusive license to provide preclinical oncology drug development and validation services using HUB Organoid Technology, including access to HUB’s highly characterized tumor organoid biobank. Our groundbreaking platform enables the combination of tumor organoids with fibroblasts and immune cells, creating a reconstituted tumor microenvironment. This setup is ideal for evaluating immunotherapies, studying cell interactions, and investigating the tumor microenvironment's role in drug response. Discover the potential of our co-culture systems in your research: https://hubs.la/Q03cGTl50

Achieve a comprehensive understanding of drug efficacy thanks to an 80% overlap between our organoid biobank and PDX collection. With an 80% overlap between our organoid biobank and PDX collection, along with patient-matched non-diseased models, you can assess on- and off-target effects accurately, leading to more predictive and translatable results. Explore our matched models for robust preclinical insights: https://hubs.la/Q03cGQk80

Speed is crucial in drug development. Our organoid platform is your key to success, providing quick turnaround times for a selection of our 730+ biobank models, covering 22 cancer indications. Our large panel screening capability allows for simultaneous testing across multiple models, providing comprehensive data to drive your projects forward efficiently. Learn how our organoid platform can expedite your research: https://hubs.la/Q03ct6z90

Unlock unparalleled insights into patient responses with our standardized organoid platform. As the only holder of an exclusive license to provide preclinical oncology drug development and validation services using HUB Organoid Technology, our extensive biobank boasts over 730 well-characterized patient-derived organoid models, covering 22 cancer indications. By integrating high-throughput screening, co-culture systems, biomarker analysis, and cutting-edge imaging, we accelerate the development of effective therapies. Explore our organoid platform and elevate your research: https://hubs.la/Q03cfzj80

With our 3D organoid models, you can depend on our commitment to quality and reproducibility. Our organoid biobank adheres to the highest quality control standards, ensuring contamination-free models for your research. With standardized procedures and highly automated workflows, our drug testing assays deliver consistent and reproducible results, enabling confident decision-making in your drug development. Discover the reliability of our organoid models: https://hubs.la/Q03c4P7c0

本日は弊社主催のシンポジウムにご来場いただき、有難うございました。医薬品開発におけるトランスレーショナルリサーチについての、アカデミア、CRO、製薬間での素晴らしいディスカッションとなりました。残りの2日間、3月18日と19日は引き続きAPPW2025展示ブース(ブース番号37)で、皆様のお越しをお待ちしております。 Thank you so much for joining our symposium today. It was a great discussion among academia, CRO and pharmaceutical company on translational research for drug discovery. We still look forward to seeing you at our exhibition booth (booth number 37) on the remaining two days, March 18th and 19th at APPW2025. https://hubs.la/Q039lxF80 #オンコロジー #腫瘍学 #創薬技術 #免疫腫瘍学 #医薬品開発 Crown Bioscience

In oncology research, the development of targeted biologics, such as Antibody-Drug Conjugates (ADCs), relies on the precise identification and validation of therapeutic targets. Our latest blog post explores how integrating advanced experimental models and analytical tools can enhance the accuracy of target and lead selection, leading to more effective and personalized therapies. Read the full blog post or listen on the go to discover how a holistic, data-driven approach is transforming biologic development in oncology. https://hubs.la/Q039PtGS0

Earlier today we announced John Gu as our new Chief Executive Officer (CEO). Tim Lowery, President of JSR Life Sciences, Crown Bioscience's parent company, commented on this development. Learn more https://hubs.ly/Q03bxQ9X0